SCHEMBL2141982

SCHEMBL2141982

CC(=O)O[C@@H](CNC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HTT P42858 1/20 0.49
SYK P43405 1/20 0.48
SLC1A3 P43003 1/20 0.47
SLC1A1 P43005 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
KEAP1 Q14145 2/20 0.46
NFE2L2 Q16236 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CTSK P43235 3/20 0.45
CTSS P25774 2/20 0.45
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2141987 1.00 ALDH1A1 (0.53) ALDH1A1LMNASMN1; SMN2HTTSYK
SCHEMBL11455100 0.86 SLC1A3 (0.57) ALDH1A1LMNASMN1; SMN2HTTSLC1A3
SCHEMBL2142193 0.86 ALDH1A1 (0.47) ALDH1A1LMNASMN1; SMN2HTTSYK
SCHEMBL2142198 0.86 ALDH1A1 (0.47) ALDH1A1LMNASMN1; SMN2HTTSYK
SCHEMBL9124535 0.83 FOLH1 (0.57) LMNASMN1; SMN2HTTSLC1A3SLC1A1
SCHEMBL9124548 0.83 FOLH1 (0.57) LMNASMN1; SMN2HTTSLC1A3SLC1A1
SCHEMBL19618207 0.81 LMNA (0.56) ALDH1A1LMNASMN1; SMN2HTTSLC1A3
SCHEMBL6154004 0.81 HTT (0.50) ALDH1A1LMNASMN1; SMN2HTTSYK
SCHEMBL6153937 0.81 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2HTTSYK
SCHEMBL6154638 0.81 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2HTTSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160152653-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS MEIJI SEIKA PHARMA CO LTD (JP) 2016-06-02 US disclosed
US-9260465-B2 Aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-02-16 US disclosed
EP-2036917-B1 NOVEL AMINOGLYCOSIDE ANTIBIOTIC MEIJI SEIKA PHARMA CO LTD (JP) 2015-10-07 EP disclosed
US-20130345411-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2013-12-26 US disclosed
US-8541394-B2 Aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2013-09-24 US disclosed
US-20120165283-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS KOBAYASHI YOSHIHIKO (JP) 2012-06-28 US disclosed
US-8148504-B2 Aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2012-04-03 US disclosed
US-8148504-B2 Aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2012-04-03 US disclosed
US-20090186841-A1 Novel aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-07-23 US disclosed
US-20090186841-A1 Novel aminoglycoside antibiotics MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-07-23 US disclosed
EP-2036917-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTIC MEIJI SEIKA KAISHA LTD. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345411-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS ATP6V1B1, REN, NRDC ALDH1A1 819/4885LMNA 2792/4885SMN1; SMN2 4458/4885
US-20120165283-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS ATP6V1B1, REN, NRDC ALDH1A1 819/4885LMNA 2792/4885SMN1; SMN2 4458/4885
US-20160152653-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTICS ATP6V1B1, REN, NRDC ALDH1A1 819/4885LMNA 2792/4885SMN1; SMN2 4458/4885
US-20090186841-A1 Novel aminoglycoside antibiotics ATP6V1B1, REN, NRDC ALDH1A1 819/4885LMNA 2792/4885SMN1; SMN2 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.